Form 4: IO Biotech Director Christian Elling Acquires Stock Options

Christian Elling, a director at IO Biotech, acquired stock options for 45,642 shares of common stock on June 6, 2024.

Summary

• Christian Elling, a director of IO Biotech, Inc., filed a Form 4 on June 7, 2024.
• The form reports a transaction that occurred on June 6, 2024, where Elling acquired stock options for 45,642 shares of IO Biotech's common stock at an exercise price of $1.25.
• These options vest on June 6, 2025, contingent upon Elling's continued service and are subject to full acceleration upon a change of control.
• Following the reported transaction, Elling directly owns 45,642 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the holdings of a company director.
• The vesting conditions of the stock options align the director's interests with the long-term success of the company.

Key Dates